Plus ça change : Renée Fox and the Sociology of Organ Replacement Therapy

2020 ◽  
Vol 50 (2) ◽  
pp. 6-7
Author(s):  
Joel E. Frader ◽  
Charles L. Bosk
2015 ◽  
Vol 35 (3) ◽  
pp. 297-305 ◽  
Author(s):  
Sharon J. Nessim ◽  
Joanne M. Bargman ◽  
S. Vanita Jassal ◽  
Matthew J. Oliver ◽  
Yingbo Na ◽  
...  

BackgroundA significant proportion of peritoneal dialysis (PD) patients receive an initial period of hemodialysis (HD) before transitioning to PD (“PD-switch”). We sought to better understand the risks of PD technique failure (TF) and mortality for those patients compared with patients starting with PD as their first dialysis modality (“PD-first”).MethodsUsing Canadian Organ Replacement Register data, we compared the risk of PD TF between PD-first and PD-switch patients within the first year after HD initiation. In a secondary analysis, the PD-switch patients were stratified into three groups based on timing of the switch from initial HD to PD as follows: 0 – 90 days, 91 – 180 days, and 181 – 365 days. Each group was compared with PD-first patients for risk of PD TF and death.ResultsBetween 2001 and 2010, 9404 patients initiated PD as their first renal replacement therapy, and 3757 switched from HD to PD. After multivariable adjustment, the risk of PD TF was higher among PD-switch patients than among PD-first patients [adjusted hazard ratio (AHR): 1.37; 95% confidence interval (CI): 1.26 to 1.49], particularly within the first year after the switch from HD to PD (AHR: 1.51; 95% CI: 1.36 to 1.68). There was no association between time on HD within the first year and subsequent risk of PD TF. For all the stratified PD-switch groups, death rates were higher than those for PD-first patients.ConclusionsCompared with patients who start renal replacement therapy with PD, those who transfer from HD to PD within the first year on dialysis experience higher rates of PD TF and death, with the highest risk being observed in the initial year after the switch to PD.


Author(s):  
Chad D. Jensen ◽  
Amy F. Sato ◽  
Elissa Jelalian ◽  
Elizabeth R. Pulgaron ◽  
Alan M. Delamater ◽  
...  

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Masamitsu Oshima ◽  
Kaoru Inoue ◽  
Kei Nakajima ◽  
Tetsuhiko Tachikawa ◽  
Hiromichi Yamazaki ◽  
...  

Open Biology ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 190010 ◽  
Author(s):  
Etsuko Ikeda ◽  
Miho Ogawa ◽  
Makoto Takeo ◽  
Takashi Tsuji

In this decade, substantial progress in the fields of developmental biology and stem cell biology has ushered in a new era for three-dimensional organ regenerative therapy. The emergence of novel three-dimensional cell manipulation technologies enables the effective mimicking of embryonic organ germ formation using the fate-determined organ-inductive potential of epithelial and mesenchymal stem cells. This advance shows great potential for the regeneration of functional organs with substitution of complete original function in situ . Organoids generated from multipotent stem cells or tissue stem cells via establishment of an organ-forming field can only partially recover original organ function owing to the size limitation; they are considered ‘mini-organs’. Nevertheless, they hold great promise to realize regenerative medicine. In particular, regeneration of a functional salivary gland and an integumentary organ system by orthotopic and heterotopic implantation of organoids clearly points to the future direction of organ regeneration research. In this review, we describe multiple strategies and recent progress in regenerating functional three-dimensional organs, focusing on ectodermal organs, and discuss their potential and future directions to achieve organ replacement therapy as a next-generation regenerative medicine.


1995 ◽  
Vol 25 (1) ◽  
pp. 134-150 ◽  
Author(s):  
S. Fenton ◽  
M. Desmeules ◽  
P. Copleston ◽  
G. Arbus ◽  
D. Froment ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document